Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,601 matching trials from the live ClinicalTrials.gov search.
Recruiting No phase listed Observational

Busulfan Sample Collection Study

NCT05711732
Conditions
Subjects Treated With Busulfan
Interventions
MyCare Oncology Busulfan Assay Kit
Diagnostic Test
Lead sponsor
Saladax Biomedical, Inc.
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • New Brunswick, New Jersey • Houston, Texas
Conditions
Multiple Myeloma
Interventions
Total Skeletal Irradiation
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Conditions
Multiple Myeloma
Interventions
Safety and efficacy assessments
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 4 more
Conditions
Myeloma, Plasma-Cell, Lymphoma, Malignant, Myeloproliferative Disorders, Myelodysplastic Syndromes, Waldenstrom's Macroglobulinemia
Interventions
Reduced intensity conditioning with allogeneic transplant
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Multiple Myeloma
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
4,253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
43
States / cities
Little Rock, Arkansas • La Jolla, California • Santa Rosa, California + 39 more
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, PD 0332991
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Chicago, Illinois • Kansas City, Kansas • Westwood, Kansas + 9 more
Completed Phase 1Phase 2 Interventional Results available

Daratumumab for the Treatment of Patients With AL Amyloidosis

NCT02841033
Conditions
AL Amyloidosis
Interventions
daratumumab
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Multiple Myeloma
Interventions
A (Thalidomide + Dexamethasone), B (Placebo + Dexamethasone)
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
26
States / cities
Hoover, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Conditions
Diffuse Large B Cell Lymphoma, Multiple Myeloma
Interventions
PointCheck
Diagnostic Test
Lead sponsor
Leuko Labs, Inc.
Industry
Eligibility
10 Years and older
Enrollment
210 participants
Timeline
2025 – 2027
U.S. locations
5
States / cities
Honolulu, Hawaii • Louisville, Kentucky • Boston, Massachusetts + 2 more
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Nivolumab, Ixazomib, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
Andrew Yee, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Conditions
Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Myeloma
Interventions
Placebo, Minocycline
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Systemic Amyloidosis
Interventions
Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Male Infertility, Nonobstructive Azoospermia, Azoospermia
Interventions
Platelet rich plasma
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Conditions
Multiple Myeloma
Interventions
Vermurafenib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Multiple Myeloma
Interventions
Linvoseltamab
Biological
Lead sponsor
Dickran Kazandjian, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Miami, Florida
Conditions
Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
345
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more
Conditions
Hematologic Malignancies
Interventions
Romiplostim
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Multiple Myeloma, Refractory
Interventions
Pembrolizumab, Belantamab mafodotin, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Conditions
Optic Neuritis, Myelitis, Myelitis, Transverse
Interventions
High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
lenalidomide, melphalan, prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
carfilzomib, dexamethasone, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Duarte, California • Rochester, Minnesota • St Louis, Missouri
Completed Phase 2 Interventional Results available

Trial Of Double Umbilical Cord Blood Transplantation

NCT00763490
Conditions
Hematological Malignancies
Interventions
Full intensity, double umbilical cord, stem cell transplant, Flu/Bu4 conditioning regimen, Total Lymphoid Irradiation (TLI), Graft versus Host Disease prevention (GVHD prophylaxis), Mycophenolate Mofetil
Procedure · Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan